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Abstract
From November 4th- 6th 2011, the 3rd NEUROWIND e.V. meeting was held in Motzen, Brandenburg, Germany. Like
in the previous years, the meeting provided an excellent platform for scientific exchange and the presentation of
innovative projects for young colleagues in the fields of neurovascular research, neuroinflammation and
neurodegeneration. As kick-off to the scientific sessions, Reinhard Hohlfeld, Head of the Institute for Clinical
Neuroimmunology in Munich, gave an illustrious overview on the many fascinations of neuroimmunologic
research. A particular highlight on the second day of the meeting was the award of the 1’st NEUROWIND e.V. prize
for young academics in the field of experimental neurology. This award is posted for young colleagues under the
age of 35 with a significant achievement in the field of neurovascular research, neuroinflammation or
neurodegeneration and comprises an amount of 20.000 Euro, founded by Merck Serono GmbH, Darmstadt.
Germany. The first prize was awarded to Ivana Nikic from Martin Kerschensteiner’s group in Munich for her brilliant
work on a reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis,
published in Nature Medicine in 2011. This first prize award ceremony was a great incentive for the next call for
proposals now upcoming in 2012.
Summary of the scientific contributions to the
NEUROWIND e.V. meeting 2011
Contributions on neuroimmunology and
neurodegeneration - interactions between the immune
system and the nervous system
In 2011, presentations in the field of neuroimmunology
dealt with multiple sclerosis (MS), chronic inflammatory
demyelinating polyneuropathy (CIDP), antibody-
mediated diseases (stiff-person-syndrome - SPS, Batten
disease, neuromyelitis optica - NMO, limbic encephali-
tis) and Shiga toxin (Stx)-producing Escherichia coli
(STEC) infection.
Anne Willing from Manuel Friese’s lab in Hamburg
demonstrated that IL-17 production by CD8+ T cells is
mainly restricted to CD161 high cells. In MS patients,
CD4 + CD161+ cells are significantly increased in the
CSF. In contrast CD161 high CD8+ cells belonging to
mucosal associated invariant T cells (MAIT) reacting to
bacteria but not viruses are significantly reduced in per-
ipheral blood and CSF in MS.
Christina Heinemann from Thomas Korn’s laboratory
in Munich investigated the role IL-23 in the priming of
encephalitogenic T helper cell responses. Using IL-23R
knockout mice, she found that a major T cell intrinsic
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function of IL-23 is the suppression of IL-10. Thus, an
overwhelming IL-10 response rather than the lack of
Th17 cells in IL-23R KO mice confers resistance to EAE
in these animals.
The importance of microRNAs in neuroinflammation
was highlighted by Andreas Junker from Göttingen. 172
from 365 tested microRNAs were detected in inactive
MS lesions. Conversely, Andreas showed that micro-
RNA-155 was overexpressed in active MS lesions and
microRNA155 deficient mice demonstrated an amelio-
rated EAE disease course.
Another EAE project was presented by Arndt Manzel
from Ralf Linker’s group in Erlangen. Arndt investigated
the role of the sodium/fluid balance in T cell responses.
Together with recent data on the role of the renin
angiotensin system in autoimmune inflammation, these
results further underscore the notion that key players in
renal function may also impact on immune responses.
Catherina Sorbara from Martin Kerschensteiner’s
group in Munich demonstrated the importance of axo-
nal damage for sustained disability progression in MS
patients. Using two-photon microscopy of the lumbar
spinal cord, she was able to show an increased axonal
density of mitochondria in axons of EAE mice compared
to controls. This process was interpreted as a transport
deficit that might be mediated by NO and/or H2O2
production.
Sebastian Fiebiger from Berlin (group of Friedemann
Paul and Carmen Infante-Duarte) talked about oxidative
damage in neuroinflammation focusing on the role of
microglia derived NO that targets mitochondria. The
sequence of destructive events includes a reduced ATP
output and increased ONOO- leading to cytochrome C
release and degradation of cytoskeletal proteins. Within
this context the antioxidant idebenone - a synthetic ana-
logue of coenzyme Q10 is currently tested in phase I/II
trials in PPMS. In Sebastian’s studies, idebenone pro-
tected HT22 neuronal cells from glutamate induced cell
death but failed to influence the disease course of EAE
animals.
CIDP is a chronic inflammatory disease of the periph-
eral nervous system with autoimmune pathogenesis. So
far, the auto-antigen is not defined and potentially rele-
vant protein candidates include PMP22 and P0. Martin
Russwurm from Marburg (Björn Tackenberg’s group)
presented a study of quantitative expansions in antigen-
specific T cells via TCRvbeta analysis in 24 patients suf-
fering from CIDP using FACS analysis and CDR 3 spec-
tratyping before and after IVIG treatment. In CIDP
patients, increased numbers of cells with specific Vbeta
domains before IVIG treatment (in 70% of patients) in
CD4+ and CD8+ T cells were reduced under IVIG ther-
apy (in particular in CD4+ cells). CDR3 spectratyping
analysis suggested that the overrepresentation of specific
Vbeta chains was due to oligoclonal expansion of specific
T cell clones. Upon immunophenotyping, Vbeta positive
patients displayed an increase in CD95 (FAS), VLA-4 and
LFA-1 as well as a reduction of CD28 in CD4CD45RO +
cells.
Christian Geis from Würzburg gave an overview of
CNS antibodies and associated synaptic pathophysiolo-
gies including stiff person syndrome (SPS), neuromyelitis
optica (NMO) and limbic encephalitis. He introduced an
animal model of SPS achieved by passive transfer of
GAD-65 antibodies in rodents. Furthermore, he devel-
oped a model system for Batten disease, a neuropsychia-
tric disease of school-aged children using Cln3-/- mice. In
a third model, NMO pathophysiology was induced by
intrathecal injection of NMO IgG or anti-AQP-4 antibo-
dies together with complement.
The outbreak of hemolytic uremic syndrome (HUS)
and diarrhea caused by Shiga toxin-producing Escheri-
chia coli O104:H4 (STEC) in Germany during May to
July 2011 involved severe and characteristic neurologic
manifestations. Kerstin Göbel from Münster (Sven
Meuth’s lab) presented clinical and paraclinical data of 7
female, adult patients and single-cell patch-clamp record-
ings from murine thalamic relay neurons demonstrating
a direct cytotoxic effect of Shiga toxin 2 (Stx 2) on thala-
mic but not cortical neurons. This primary involvement
of the thalamus in STEC infection might be related to
the gender-specific high expression of the Stx 2 receptor
globotriaosylceramide (GB3).
In further sessions, several presentations focused on
degenerative diseases of the peripheral and central ner-
vous system comprising studies on neuropathies, Parkin-
son’s disease (PD), Huntington’s disease (HD) and
Alzheimer’s disease (AD). In a comprehensive study on
toxic neuropathies, Wolfgang Böhmerle from Berlin (lab
of Matthias Endres) focused on the role of calcium in
toxic neuropathies, either induced via taxols and endo-
plasmic reticulum stress or salinomycin which induced
mitochondrial damage.
Gunnar Hargus from Münster analyzed the potential
of human pluripotent stem cells in models of PD. Pluri-
potent stem cells can generate cells of the three germ
layers, and have unlimited self-renewal capacity. Of par-
ticular interest are so called iPS cells which are gener-
ated by reprogramming of differentiating somatic cells
via specific protocols.
Another study on PD was presented by Joachim Göbel
from Günther Höglinger’s group in Marburg (now
Munich). The use of LUHMES cells to generate synu-
clein transfected tyrosin hydroxylase positive neurons as
a model for cytotoxicity provides an elegant paradigm to
test mechanism of disease or protective compounds.
Using GFP transgenic bone marrow chimera and APP
PS1 transgenic mice, Karin Kierdorf from Marco Prinz’s
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lab in Freiburg presented data on the distinct roles of
microglia and myeloid cells in this model mimicking
aspects of AD.
Gisa Ellrichmann from the group of Ralf Gold in
Bochum gave a talk on the protective role of fumaric
acid esters in the R6/2 and YAC128 models of HD.
Finally, Gwendolyn Behrend’s presentation (from the
lab of Magdalena Götz in Munich) focused on reactive
glia dedifferentiation in neurodegeneration. She showed
that local differentiation of astrocytes into neural stem
cells is possible in acute lesions. In contrast, there is lit-
tle to no de-differentiation in chronic models of AD.
Contributions on stroke and vascular pathology
As in the past 2010 meeting, one key topic in the neurovas-
cular field was again related to the role of immune
mechanisms and inflammatory circuits in the pathophy-
siology of stroke. Peter Ludewig from Tim Magnus’s group
in Hamburg provided conclusive evidence of a beneficial
function of CEACAM-1 during ischemic brain damage.
CEACAM-1 knockout mice developed significantly larger
infarctions after middle cerebral artery occlusion (MCAO)
and this was due to enhanced blood-brain-barrier leakage
and impaired neurovascular recovery.
By using different immunological mouse models
Juliane Klehmet from the Charité in Berlin (group of
Andreas Meisel) could show that the enhanced infiltra-
tion of CNS antigen specific T cells might be one impor-
tant mediator of stroke-induced immunodepression.
Interestingly, antibiotic treatment was able to reverse the
priming of CNS antigen-specific T cells in this setting
and thus, may have the potency to counteract harmful
immunodepression.
Christiane Albert-Weißenberger from Christoph
Kleinschnitz’s lab in Würzburg presented preliminary
data on the involvement of the proinflammatory kallik-
rein-kinin system after diffuse traumatic brain injury.
Mice lacking the kinin receptor B1 but not kinin receptor
B2 developed less severe neurological deficits when ana-
lyzed in the weight drop model. This protective effect,
which was restricted to the later phase after brain trauma
only, is probably related to reduced astroglia activation
and the prevention of diffuse axonal damage.
Finally, Martin Busch, doctoral student in the group of
Alma Zernecke at the Rudolf-Virchow Center in Würz-
burg, explained how miRNA could be involved in the regu-
lation of dendritic cell function during atherosclerosis.
A classical neuroprotection approach was presented by
Christoph Harms, Junior Professor at the Charité in Ber-
lin, who talked about an interesting molecule called
apoptosis repressor with card domain (ARC) and its
pleiotropic functions in in vitro and in vivo models of
ischemic stroke.
Another focus of this year’s meeting was on intracer-
ebral hemorrhage. In accordance with the findings in
brain ischemia, Bernd Kallmünzer from Erlangen
showed that the hematopoietic growth factor G-CSF is
also able to ameliorate functional deficits in models of
intracranial bleeding (ICB). The underlying mechanisms,
amongst others modulation of inflammation or prolif-
eration of stem cells, are currently under investigation.
Arne Lauer from Christian Foerch’s group in Frank-
furt discussed the clinically relevant question whether or
not the novel anticoagulant Dabigatran fosters hema-
toma growth after experimentally induced ICB in
rodents. Interestingly, Dabigatran did not lead to
increased bleeding volumes neither in the collagenase
model nor after laser-induced rupture of cerebral blood
vessels.
Two additional studies addressed the hot topic of vas-
cular dementia. Anna Karpinska reported on the latest
findings from the group of Martin Dichgans in Munich.
By establishing a novel fluorescence-based single mole-
cule bioassay (SIFT) they are now able to characterize
NOTCH aggregation processes in vitro which could
lead to a better understanding of the rare CADASIL
syndrome.
Stefanie Schreiber from the German Center for Neu-
rodegenerative Disorders (DZNE) in Magdeburg made
use of spontaneously hypertensive stroke-prone rats
(SHRSP) to study the pathologic cascade of cerebral
microangiopathy (small vessel disease). She could show
that intravascular accumulations of erythrocytes, parsi-
moniously interpreted as stases and associated with
blood-brain barrier disturbances, is the initial step of
this pathological cascade which is subsequently followed
by microbleeds, mircothromboses and (hemorrhagic) tis-
sue infarctions.
Finally, Maria Adele Rüger from Cologne reported on
an elegant PET-based imaging method to non-invasively
trace the mobilization of endogenous neural stem cells
after focal brain ischemia.
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